RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:MBC phase 3
hello Normandt
According to onc we still have a fast track for our phase 3 mbc indication and if they could run the trial back in 2017 with 400 patients , it is diffiucult to comprehend that with all the work done to bring us where we are that the company is saying they will run the exact same 2 arm trial with 550 patients...The trial will most likely not start unil 2025 as they said they are waiting on the fda which is 6-9 months and then set up the sites so the trial most likely could not start until 2025 IMO only and with the extra 150 patients that would extend the trial at least another year.
Of course there wiill be opposing view points and i get it but all that time and money lost to now run the same trial with the hopeful addition of the biomarkers to help reduce patient enrollment.
Let's just hope that panc gets going and leave all the rest behind us.